203 related articles for article (PubMed ID: 25222881)
1. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Cazzola M; Calzetta L; Segreti A; Facciolo F; Rogliani P; Matera MG
COPD; 2015 Apr; 12(2):175-81. PubMed ID: 25222881
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
[TBL] [Abstract][Full Text] [Related]
4. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG
Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
[TBL] [Abstract][Full Text] [Related]
5. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
Wedzicha JA; Dahl R; Buhl R; Schubert-Tennigkeit A; Chen H; D'Andrea P; Fogel R; Banerji D
Respir Med; 2014 Oct; 108(10):1498-507. PubMed ID: 25135743
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Pelaia G; Maselli R; Matera MG
Pharmacology; 2014; 94(5-6):249-58. PubMed ID: 25471458
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
9. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
10. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
[TBL] [Abstract][Full Text] [Related]
11. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR; Hurst JR; Frent SM; Larbig M; Fogel R; Guerin T; Banerji D; Patalano F; Goyal P; Pfister P; Kostikas K; Wedzicha JA
Am J Respir Crit Care Med; 2018 Aug; 198(3):329-339. PubMed ID: 29779416
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
14. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
Blais CM; Davis BE; Cockcroft DW
Respir Res; 2017 Aug; 18(1):146. PubMed ID: 28768531
[TBL] [Abstract][Full Text] [Related]
15. Effects of (a Combination of) the Beta
Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
Cells; 2021 May; 10(5):. PubMed ID: 34069899
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
[TBL] [Abstract][Full Text] [Related]
20. Indacaterol for the treatment of chronic obstructive pulmonary disease.
Matera MG; Rogliani P; Cazzola M
Expert Opin Pharmacother; 2015 Jan; 16(1):107-15. PubMed ID: 25418284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
